Evidence map›Paper›PMID 42402173›Full record

ArticleBiotechnology and bioengineering2026

Hemopexin Purification From Human Cohn Fraction IV Paste and Its Biophysical Characterization and Functional Evaluation in Sickle Cell Disease Mice.

Shuwei Lu, Saini Setua, Mohd A Khan, Aaradhya Bansal, Quintin O'Boyle, Pedro Cabrales, David C Irwin, Paul W Buehler, Andre F Palmer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuwei LuWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, College of Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-2454-7820
Saini SetuaDepartment Pediatrics, Center for Blood Oxygen Transport and Hemostasis, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-9874-6948
Mohd A KhanWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, College of Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-4698-2332
Aaradhya BansalWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, College of Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0009-0006-6327-0309
Quintin O'BoyleWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, College of Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-1499-9620
Pedro CabralesDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-8794-2839
David C IrwinCardiovascular and Pulmonary Research Group, Department of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0002-1743-8266
Paul W BuehlerDepartment Pediatrics, Center for Blood Oxygen Transport and Hemostasis, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0003-0687-3008
Andre F PalmerWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, College of Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-3378-3772

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Bioengineering a Dual Function Protein Construct to Detoxify Heme and HemoglobinR01HL159862 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2021 to 2024
$2.6M
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysisR01HL162120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2022 to 2025
$2.6M
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseasesR01HL158076 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BUEHLER, PAUL WERNER, IRWIN, DAVID CHARLES · 2022 to 2025
$2.5M
NCI NIH HHS P30 CA016058NHLBI NIH HHS R01 HL158076NHLBI NIH HHS R01 HL159862NHLBI NIH HHS R01 HL162120NIH HHS R01HL158076NIH HHS R01HL159862NIH HHS R01HL162120U.S. Army Medical Research Acquisition Activity HT94252410238
6 · The paper itself

Abstract

Hemopexin (Hpx) is an acute phase plasma protein that is responsible for sequestration and removal of cell-free heme with very high affinity (K

Indexed as

Anemia, Sickle CellHemopexinAnimalsChromatography, AffinityDisease Models, AnimalElectron Spin Resonance SpectroscopyHumansMiceHemopexin

Identifiers

PMID42402173
PMCPMC13521458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.